Table 3.

PCR standard curve data.

	In vivo study 1 (Figure 1)				In vivo study 2 (Figure 3)
Primers	Lin. slope	Efficiency (%)	Range (CT)	Primer conc.	Lin. slope	Efficiency (%)	Range (CT)	Primer conc.
miR-1	−3.12	106	18.3–22.3	20X	−3.55	94	21.6–24.9	20X
miR-133a	−3.18	104	18.6–22.7		−3.22	103	20.4–23.3
miR-133b	−3.49	95	19.6–22.9		−3.27	102	19.7–22.7
miR-206	3.5	95	21.6–24.6		−3.21	104	23.2–26.2
RNU48	-	-	-	-	−3.38	98	27.4–30.5
MYOD	-	-	-	-	−3.42	97	24.9–29.0	F: 300 nM R: 300 nM
MYOG	-	-	-	-	−3.15	105	22.7–26.5
MYF-5	-	-	-	-	−3.28	101	25.5–29.3
AR	-	-	-	-	−3.51	95	23.7–28.0
18S	−3.26	102	14.7–18.5	F: 300 nM R: 300 nM	−3.44	97	13.0–17.2
	Mice study (Figure 4)					In vitro study (Figure 5)
miR-1	−3.28	101	18.1–21.8	20X	−3.47	96	28.1–32.3	20X
miR-133a	−3.35	99	16.6–20.7		−3.59	92	24.9–29.2
miR-133b	−3.35	99	17.2–21.3		3.46	96	24.5–28.7
miR-206	−3.41	97	24.4–27.5		−3.49	95	22.9–27.1
RNU48	-	-	-	-	−3.16	105	26.8–30.7
MYOD/Myod	−3.25	102	22.8–26.8	F: 300 nM R: 300 nM	−3.47	96	22.7–26.9	F: 300 nM R: 300 nM
MYOG/Myog	−3.83	88	25.3–29.1		−3.36	99	20.5–24.5
MYF-5/Myf-5	−3.8	84	26.1–31.0		−3.53	94	22.5–26.8
AR/Ar	−3.19	104	22.9–25.8		−3.46	96	27.1–31.2
18S	−3.36	99	13.4–17.4		−3.5	95	13.7–18.1

PCR efficiency, linearity slope, cycle threshold range and concentration for each primer used in the study.